Comparative Pharmacology
Head-to-head clinical analysis: CLINIMIX E 5 15 SULFITE FREE W ELECT IN DEXTROSE 15 W CALCIUM IN PLASTIC CONTAINER versus PROSOL 20 SULFITE FREE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLINIMIX E 5 15 SULFITE FREE W ELECT IN DEXTROSE 15 W CALCIUM IN PLASTIC CONTAINER versus PROSOL 20 SULFITE FREE IN PLASTIC CONTAINER.
CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER vs PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CLINIMIX E 5/15 is a parenteral nutrition solution that provides essential amino acids, electrolytes, and dextrose for intravenous use. Amino acids serve as building blocks for protein synthesis, dextrose provides calories for energy metabolism, and electrolytes maintain fluid and electrolyte balance. Calcium is essential for bone mineralization, neuromuscular function, and enzyme activation.
Propofol is a short-acting intravenous anesthetic agent that potentiates GABA-A receptor activity, resulting in rapid loss of consciousness through inhibition of neuronal firing in the central nervous system.
Intravenous infusion. Typical adult dose: 1.5–2.0 L/day of CLINIMIX E 5/15 (providing 75–100 g amino acids and 225–300 g dextrose per day) administered via central line; rate determined by glucose tolerance and fluid status.
Intravenous infusion: 20 mL/kg (4 g/kg) as a 20% solution administered over 2-4 hours. May repeat up to 100 mL/kg/day if needed.
None Documented
None Documented
Components have variable half-lives: amino acids ~0.5-1 h; dextrose ~2-4 h; electrolytes depend on renal function. Terminal half-life not applicable as a mixture.
Terminal elimination half-life is approximately 1–2 hours in healthy individuals; may be prolonged in renal impairment due to accumulation of metabolites.
Renal excretion of amino acids and electrolytes; dextrose is metabolized to CO2 and water, with minimal renal excretion. Biliary/fecal elimination is negligible (<2%).
Renal excretion of unchanged drug is minimal (<5%). The majority is metabolized via the tricarboxylic acid cycle to CO2 and water. Biliary/fecal elimination is negligible.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution